| Domain | Key quantitative findings | Practical interpretation | Evidence type and date |
|---|---|---|---|
| Disease definition / epidemiology | Malignant ovarian germ cell tumors (MOGCTs) are rare, comprising 2–5% of ovarian cancers; annual incidence reported as 4:100,000 and approximately 4 per 1,000,000 women; most occur at ages 10–25 years with median diagnosis age 18; 60–70% present as early-stage disease; common symptoms are abdominal pain (87%) and palpable mass (85%) (pqac-00000006, pqac-00000002, pqac-00000017) | Rare, usually adolescent/young-adult ovarian cancers that often present early but require rapid evaluation because symptoms are nonspecific | Human clinical review, 2023; review with compiled epidemiology, 2023 |
| Major subtypes | Dysgerminoma accounts for 35–50% globally; dysgerminoma and immature teratoma together comprise 65–70% of cases; yolk sac tumor (YST) 14.5%; mixed germ cell tumors 5.3%; embryonal carcinoma ~4%; bilateral disease occurs in 10–15% of pure dysgerminomas and 5–10% of mixed tumors (pqac-00000002, pqac-00000000) | Histology strongly determines marker use, surgical decisions, and adjuvant chemotherapy needs | Human clinical and molecular reviews, 2023 |
| Biomarkers | AFP is elevated in YST and can be elevated in embryonal carcinoma/immature teratoma; β-hCG is associated with choriocarcinoma and some embryonal carcinomas; LDH is used in dysgerminoma; in a 2024 pelvic YST series, AFP rose in all 16/16 and CA125 increased in 58.33% (7/12); YST ultrasound series showed 81.25% ovarian location (13/16) with rich vascularity in solid/cystic-solid lesions (pqac-00000002, pqac-00000001) | AFP/β-hCG/LDH remain the core clinical markers; imaging plus markers helps distinguish subtype and guide fertility-preserving planning | Human clinical review, 2023; single-center retrospective imaging/pathology study, 2024 |
| Genomics / epigenetics | Overall mutation burden is low; chromosome 12p gain is a keystone feature, observed in 44% (15/34) of malignant GCTs in one series and in 10/14 tumors in patients <15 years in another summary; KIT was the most significantly mutated gene with 4/24 cases (16.7%) in a genetic landscape study; PIK3CA amplification occurred in 21.8% (19/87) and AKT amplification in 20.6% (18/87); pediatric cohort copy-number gains included 20q (57%) and 12p (39%), with 40% of the 12p-gain group carrying i(12p); dysgerminomas/germinomas are globally hypomethylated, while more differentiated tumors such as YST are relatively hypermethylated; 8,481 differentially methylated regions were identified in one pediatric cohort; miR-371~373 and miR-302 clusters are recurrently overexpressed across malignant GCTs (pqac-00000021, pqac-00000020, pqac-00000022) | Biology is driven more by copy-number/epigenetic dysregulation than high mutational burden; KIT/RAS/PI3K and methylation states are the main molecular leads for stratification and research | Human molecular review synthesizing genomic/epigenetic studies, 2023 |
| Standard treatment | Stage IA dysgerminoma and grade 1 stage IA immature teratoma: unilateral salpingo-oophorectomy (USO) with surveillance; higher-risk stage I disease often receives 3–4 cycles BEP; stages II–IV generally receive surgery plus 3–4 cycles BEP, with EP considered in older patients; stage IA pure dysgerminoma has a surgery-only recurrence rate of 15–25%; BEP doses summarized as bleomycin 30 IU, cisplatin 20 mg/m² days 1–5, etoposide 100 mg/m² days 1–5 every 3 weeks for 3–4 cycles; ongoing phase III MOGCT-01 randomizes paclitaxel/carboplatin vs BEP, planned enrollment 129 (pqac-00000012, pqac-00000013, pqac-00000016, pqac-00000014) | Fertility-sparing surgery is standard whenever feasible; BEP remains the backbone, but de-escalation/substitution strategies are under active testing to reduce toxicity | Human clinical reviews, 2023; ClinicalTrials.gov registry updated 2023 |
| Prognosis / fertility | Early-stage survival reported as 82–100% and late-stage survival as 75%; stage I disease has about 90% long-term disease-free survival; in one long follow-up fertility-preservation cohort, 42/45 women achieved pregnancy, with 65 pregnancies and 56 births among 40 survivors; another cohort had 31/39 patients with 33 uneventful pregnancies; 75.6% maintained regular menstruation after treatment; published pregnancy rates range 18.8–55.7% (pqac-00000011, pqac-00000017) | Cure rates are high and post-treatment fertility is often preserved, supporting conservative surgery and survivorship counseling | Human clinical review summarizing cohort studies, 2023 |
| Relapse / current research | Recurrences commonly occur within 2 years and often involve peritoneal/retroperitoneal lymph nodes; more than 50% of relapsed YST patients die of disease; salvage regimens include TIP, VeIP, and TI-CE with stem-cell support; targeted agents such as everolimus, imatinib, sunitinib, and pazopanib showed reported response rates of 0–13%; brentuximab vedotin produced responses in 2/9 patients (22%); accelerated BEP is under phase III evaluation in GCTs (NCT02582697) and ovarian-specific MOGCT-01 compares paclitaxel/carboplatin with BEP (pqac-00000016, pqac-00000018, pqac-00000005, pqac-00000014) | Relapse remains the main unmet need; current research focuses on optimizing salvage chemotherapy and testing lower-toxicity or targeted/immunologic approaches, but evidence is still limited | Human clinical and molecular reviews, 2023; clinical trial registry updated 2023 |
| Models | Ovarian-specific models remain scarce; NOY1/NOY2 were the first ovarian YST cell lines; cisplatin-resistant NOY1-CR became 22.3-fold more cisplatin-resistant than parent cells; GSTA1 overexpression was linked to resistance and its inhibition restored cisplatin sensitivity; TC587 is a YST line expressing AFP and SALL4 with NRAS, KIT, KMT2C, RSF1, and TP53 mutations; NOY1-CR formed larger mouse xenografts and showed CAM micrometastasis; a pediatric ovarian YST PDX treated with bleomycin/etoposide/cisplatin mirrored clinical response; the review states no established dedicated ovarian GCT PDX platform was yet available broadly (pqac-00000019, pqac-00000023) | Preclinical work is possible but limited by model scarcity; current models are strongest for studying cisplatin resistance and candidate targeted therapies in YST | In vitro/in vivo model review, 2023 |


*Table: Compact evidence matrix summarizing the highest-yield disease, molecular, diagnostic, treatment, prognosis, relapse, and model findings for malignant ovarian germ cell tumors. It is useful for quickly transferring supported facts into a disease knowledge-base entry.*